BridgeMD
New treatment option for Tourette Disorder
Official title Serotonin Control of Impulsivity in Tourette Disorder
ClinicalTrials.gov ID: NCT05942716
What this study is testing
What is Administration of a PET radiotracer?
Administration of a PET radiotracer is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for tourette disorder.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Tourette disorder (TD) is a neurodevelopmental disorder characterized by motor and vocal tics. It is often associated with multiple psychiatric comorbidities involving a high degree of impulsivity such as obsessive-compulsive disorders (OCD), attention-deficit hyperactivity disorders (ADHD), and intermittent explosive disorders (IED).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Male or Female
- Diagnosed with a Tourette Disorder following the DSM-5
- Age between 18-65 years
- Member of a social security scheme in France
- Freely-given informed consent to participate to this study (written form)
You likely can't join if
- Male or Female
- A serious not controlled psychiatric comorbidity
- A serious, evolving or debilitating pathology with a potential influence on the study
- Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
- Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
- Women breastfeeding
See the full eligibility criteria
- Male or Female
- Diagnosed with a Tourette Disorder following the DSM-5
- Age between 18-65 years
- Member of a social security scheme in France
- Freely-given informed consent to participate to this study (written form)
- With a current treatment by aripiprazole already scheduled
- With Tics compatible with TEP/fMRI exams
- Having (for women only) effective contraception throughout participation in the study.
- Male or Female
- A serious not controlled psychiatric comorbidity
- A serious, evolving or debilitating pathology with a potential influence on the study
- Drug-taking with serotonergic effects (e.g., amphetamine, cocaine, MDMA, SSRIs, mianserin)
- Contraindication for fMRI and PET (e.g., pacemaker, ferromagnetic implant, claustrophobia)
- Women breastfeeding
- Protected or restricted person (administratively or in judicial terms)
- Participants to another study with radiations or radiotracers since less of one year, participants to a concomitant study
- Do not speak french
The study team makes the final eligibility decision.
Where it's taking place
- Bron, France
- Paris, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bron, France; Paris, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.